Literature DB >> 18160674

Diagnosis and etiology of congenital muscular dystrophy.

R A Peat1, J M Smith, A G Compton, N L Baker, R A Pace, D J Burkin, S J Kaufman, S R Lamandé, K N North.   

Abstract

OBJECTIVE: We aimed to determine the frequency of all known forms of congenital muscular dystrophy (CMD) in a large Australasian cohort.
METHODS: We screened 101 patients with CMD with a combination of immunofluorescence, Western blotting, and DNA sequencing to identify disease-associated abnormalities in glycosylated alpha-dystroglycan, collagen VI, laminin alpha2, alpha7-integrin, and selenoprotein.
RESULTS: A total of 45% of the CMD cohort were assigned to an immunofluorescent subgroup based on their abnormal staining pattern. Abnormal staining for glycosylated alpha-dystroglycan was present in 25% of patients, and approximately half of these had reduced glycosylated alpha-dystroglycan by Western blot. Sequencing of the FKRP, fukutin, POMGnT1, and POMT1 genes in all patients with abnormal alpha-dystroglycan immunofluorescence identified mutations in one patient for each of these genes and two patients had mutations in POMT2. Twelve percent of patients had abnormalities in collagen VI immunofluorescence, and we identified disease-causing COL6 mutations in eight of nine patients in whom the genes were sequenced. Laminin alpha2 deficiency accounted for only 8% of CMD. alpha7-Integrin staining was absent in 12 of 45 patients studied, and ITGA7 gene mutations were excluded in all of these patients.
CONCLUSIONS: We define the distribution of different forms of congenital muscular dystrophy in a large cohort of mixed ethnicity and demonstrate the utility and limitations of current diagnostic techniques.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18160674     DOI: 10.1212/01.wnl.0000284605.27654.5a

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  34 in total

1.  β1D chain increases α7β1 integrin and laminin and protects against sarcolemmal damage in mdx mice.

Authors:  Jianming Liu; Derek J Milner; Marni D Boppart; Robert S Ross; Stephen J Kaufman
Journal:  Hum Mol Genet       Date:  2011-12-16       Impact factor: 6.150

2.  Target resequencing of neuromuscular disease-related genes using next-generation sequencing for patients with undiagnosed early-onset neuromuscular disorders.

Authors:  Yuri Kitamura; Eri Kondo; Mari Urano; Ryoko Aoki; Kayoko Saito
Journal:  J Hum Genet       Date:  2016-06-30       Impact factor: 3.172

3.  Recessive COL6A2 C-globular missense mutations in Ullrich congenital muscular dystrophy: role of the C2a splice variant.

Authors:  Rui-Zhu Zhang; Yaqun Zou; Te-Cheng Pan; Dessislava Markova; Andrzej Fertala; Ying Hu; Stefano Squarzoni; Umbertina Conti Reed; Suely K N Marie; Carsten G Bönnemann; Mon-Li Chu
Journal:  J Biol Chem       Date:  2010-01-27       Impact factor: 5.157

Review 4.  The collagen VI-related myopathies Ullrich congenital muscular dystrophy and Bethlem myopathy.

Authors:  Carsten G Bönnemann
Journal:  Handb Clin Neurol       Date:  2011

Review 5.  The o-mannosylation pathway: glycosyltransferases and proteins implicated in congenital muscular dystrophy.

Authors:  Lance Wells
Journal:  J Biol Chem       Date:  2013-01-17       Impact factor: 5.157

6.  Muscle-Eye-Brain disease.

Authors:  Anant M Shenoy; Jennifer A Markowitz; Carsten G Bonnemann; Kalpathy Krishnamoorthy; Aaron D Bossler; Brian S Tseng
Journal:  J Clin Neuromuscul Dis       Date:  2010-03

7.  Transgenic overexpression of the α7 integrin reduces muscle pathology and improves viability in the dy(W) mouse model of merosin-deficient congenital muscular dystrophy type 1A.

Authors:  Jinger A Doe; Ryan D Wuebbles; Erika T Allred; Jachinta E Rooney; Margaret Elorza; Dean J Burkin
Journal:  J Cell Sci       Date:  2011-06-07       Impact factor: 5.285

8.  Laminin-111 improves muscle repair in a mouse model of merosin-deficient congenital muscular dystrophy.

Authors:  Pam M Van Ry; Priscilla Minogue; Bradley L Hodges; Dean J Burkin
Journal:  Hum Mol Genet       Date:  2013-09-05       Impact factor: 6.150

9.  A study of FHL1, BAG3, MATR3, PTRF and TCAP in Australian muscular dystrophy patients.

Authors:  Leigh B Waddell; Jenny Tran; Xi F Zheng; Carsten G Bönnemann; Ying Hu; Frances J Evesson; Monkol Lek; Susan Arbuckle; Min-Xia Wang; Robert L Smith; Kathryn N North; Nigel F Clarke
Journal:  Neuromuscul Disord       Date:  2011-06-17       Impact factor: 4.296

10.  212th ENMC International Workshop: Animal models of congenital muscular dystrophies, Naarden, The Netherlands, 29-31 May 2015.

Authors:  M Saunier; C G Bönnemann; M Durbeej; V Allamand
Journal:  Neuromuscul Disord       Date:  2016-02-15       Impact factor: 4.296

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.